Squarepoint
DTIL icon

Squarepoint’s Precision BioSciences DTIL Stock Holding History

Squarepoint’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
137,106
+93,258
+213% +$656K ﹤0.01% 2844
2026
Q1 		$241K Buy
+43,848
New +$202K ﹤0.01% 3853
2025
Q1 		– Sell
-46,929
Closed -$179K – 4774
2024
Q4 		$179K Buy
+46,929
New +$343K ﹤0.01% 4511
2023
Q4 		– Sell
-3,385
Closed -$34.7K – 4098
2023
Q3 		$34.7K Buy
+3,385
New +$52K ﹤0.01% 3665
2022
Q2 		– Sell
-769
Closed -$71K – 2988
2022
Q1 		$71K Buy
769
+15
+2% +$2.04K ﹤0.01% 2651
2021
Q4 		$167K Buy
754
+404
+115% +$113K ﹤0.01% 2779
2021
Q3 		$121K Buy
+350
New +$119K ﹤0.01% 2628
2021
Q1 		– Sell
-2,108
Closed -$527K – 3224
2020
Q4 		$527K Buy
2,108
+528
+33% +$129K ﹤0.01% 1774
2020
Q3 		$292K Buy
+1,580
New +$314K ﹤0.01% 1814
2020
Q2 		– Sell
-632
Closed -$114K – 2292
2020
Q1 		$114K Sell
632
-2,242
-78% -$587K ﹤0.01% 1615
2019
Q4 		$1.2M Buy
2,874
+1,480
+106% +$465K 0.01% 1228
2019
Q3 		$351K Buy
+1,394
New +$454K ﹤0.01% 1809

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Squarepoint's DTIL Position: Q2 2026 in Review

Squarepoint increased its Precision BioSciences (DTIL) stake by 213% in Q2 2026, buying an estimated $656K and bringing the position to 137,106 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Squarepoint first reported a position in DTIL in Q3 2019 and has held it in 12 quarters since. The position peaked at $1.2M in Q4 2019. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Squarepoint held 137,106 shares of Precision BioSciences worth $1.08M as of Q2 2026.
  • Squarepoint bought 93,258 Precision BioSciences shares in Q2 2026, an estimated $656K.
  • Precision BioSciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2844 holding.
  • Squarepoint first reported a position in Precision BioSciences in Q3 2019 and has held it in 12 quarters since.
  • Squarepoint's Precision BioSciences position peaked at $1.2M in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.